July 2013

Neurosteroids as Therapeutic Leads in Psychiatry

Author Affiliations
  • 1Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri
  • 2Department of Neurobiology, Washington University School of Medicine, St Louis, Missouri
  • 3The Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine, St Louis, Missouri

Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Psychiatry. 2013;70(7):659-660. doi:10.1001/jamapsychiatry.2013.245

Considerable progress has been made in understanding how neural circuits contribute to mental processing and psychiatric disorders. This research has highlighted the importance of network dysfunction, particularly changes in the balance between excitatory and inhibitory transmission within and across brain regions that underlie cognition, emotion, and motivation. Despite progress, the development of new and more effective treatments for psychiatric disorders has lagged considerably, and present pharmacological treatments represent incremental advances over agents introduced decades ago. One approach for identifying novel treatments has involved studies of neuronal stress responses and how these responses are modulated based on the role that stress plays in psychiatric disorders. In this overview, we describe cholesterol-derived agents (called neurosteroids) that are generated endogenously in the brain and that are important modulators of neuronal stress reactions.1 We highlight the potential of these agents as targets for therapeutic drug development in several neuropsychiatric illnesses.

First Page Preview View Large
First page PDF preview
First page PDF preview